<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470418</url>
  </required_header>
  <id_info>
    <org_study_id>MHBB-009-06S</org_study_id>
    <secondary_id>R21AT003302-01A1</secondary_id>
    <nct_id>NCT00470418</nct_id>
  </id_info>
  <brief_title>Development of NIC5-15 in the Treatment of Alzheimer's Disease</brief_title>
  <official_title>Development of NIC5-15 in the Treatment of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humanetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment
      of Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent epidemiologic evidence, has suggested that diabetes mellitus significantly increases
      risk for the development of Alzheimer's disease, independent of vascular risk factors.
      Moreover, even patients who are simply insulin resistant, without frank diabetes, have been
      shown to share this elevated risk for the development of AD. As insulin's role as a
      neuromodulator in the brain has been revealed, several potential mechanisms for the
      interaction of diabetes or insulin resistance with AD have been suggested such as decreased
      cortical glucose utilization particularly in the hippocampus and entorhinal cortex; increased
      oxidative stress through the formation of advanced glycation end products; increased Tau
      phosphorylation and neurofibrillary tangle formation; and increased beta-amyloid aggregation
      through inhibition of insulin-degrading enzyme. The future treatment of AD might involve
      pharmacologic and dietary manipulations of insulin and glucose regulation

      NIC5-15 is a single, small, naturally occurring molecule. Animal studies and some human
      trials have shown NIC5-15 to be safe and a potent insulin sensitizer at doses equivalent to
      800-2000mg per day. In preclinical studies at doses higher than those previously studied in
      clinical trials, we found that NIC5-15 interferes with the accumulation of beta amyloid, an
      important step in the development of Alzheimer's pathology. These data suggest that NIC5-15
      may be a reasonable therapeutic agent for the treatment of Alzheimer Disease for two reasons:

        1. It is a -secretase inhibitor that is Notch-sparing.

        2. It is potentially an insulin-sensitizer.

      However critical safety and human efficacy studies must be conducted. This application
      proposes to conduct these early critical human studies. The goal of the studies contained in
      this proposal is to establish safety and efficacy of NIC5-15 for the treatment of AD. The
      specific objectives of this study are to:

      Specific Objective #1) Conduct a multiple dose safety study of NIC5-15 to establish safety in
      the doses that appear to block amyloid accumulation. These studies will characterize the
      safety profile, pharmacokinetics, and tolerability

      Specific Objective #2) Conduct a double blind placebo controlled pilot efficacy study of
      NIC5-15 in patients with AD. The goals of this study are to:

      A) Demonstrate feasibility for a multi-site trial that will be used to guide the design of a
      future larger effort. Demonstration of feasibility will include examination of accrual rate,
      overall recruitment, adherence to protocol, compliance with medication and willingness to
      complete a randomized trial, and lack of short term toxicity.

      B) Collect preliminary evidence of efficacy in terms of cognitive and global measures as well
      as secondary efficacy outcomes of activities of daily living, behavioral disturbances and AD
      biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessments: Number of Participants With Adverse Events</measure>
    <time_frame>Safety Labs, Physical Exams: 6 times over 7 weeks. Adverse Events assessed 21 times over the course of 7 weeks</time_frame>
    <description>vital signs, physical exam, Symptom Checklist, complete blood count, serum chemistries, urinalysis, and electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Clinical Measures of Cognition at Terminal Visit</measure>
    <time_frame>baseline and six weeks</time_frame>
    <description>Mini-Mental Status Exam (MMSE) 0(worst)-30(best); ADAS-cog 0 (best cognitive performance across multiple domains) - 70(worst); Activities of Daily Living (ADCS-ADL) 0(least capable of function in daily and instrumental activities)-54(best)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>NIC5-15</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with Alzheimer's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Alzheimer's Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIC5-15</intervention_name>
    <description>a natural product, found in many foods and plants with mild insulin sensitizing effects</description>
    <arm_group_label>NIC5-15</arm_group_label>
    <other_name>d-Pinitol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NINCDS/ADRDA criteria for probable AD

          -  MMSE between 12-27

          -  Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist
             with stable dose for at least 12 weeks

          -  Home monitoring available for supervision of medications

          -  Caregiver available to accompany patient to all visits and willing to participate in
             study as informant

          -  Fluent in English or Spanish

          -  Medical stability for this study as confirmed by review of records, internist's
             physical exam, neurological exam, and laboratory tests

          -  Stable doses of non-excluded medication

          -  No evidence of hepatic insufficiency

          -  Able to swallow oral medications

          -  Ability to participate in the informed consent process

        Exclusion Criteria:

          -  History of Diabetes Mellitus (OGTT criteria) requiring treatment with an excluded
             antidiabetic medication (see below) or history of hypoglycemia

          -  Active hepatic or renal disease

          -  Cardiac disease including history of congestive heart failure or current treatment for
             CHF; history of recent myocardial infarction

          -  Use of another investigational drug within the past two months

          -  History of clinically significant stroke

          -  History of seizure or head trauma with disturbance of consciousness within the past
             two years

          -  Major mental illness including psychotic disorders, bipolar disorder, or major
             depressive episode within the past two years Medication Exclusion

          -  Current use of oral hypoglycemic agents including sulfonylureas and meglintinides

          -  Current use of a lipid-lowering agent (excluded from Study #1, see discussion below)

          -  Current or past treatment with insulin for longer than two weeks

          -  Current use of drugs with significant anticholinergic or antihistaminic properties
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillel Grossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mssm.edu/research/centers/alzheimers-disease-research-center</url>
    <description>Mount Sinai School Of Medicine's Alzheimer's Disease Research Center</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2007</study_first_submitted>
  <study_first_submitted_qc>May 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>January 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Alzheimer Type Senile Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>clinical trial</keyword>
  <keyword>dementia</keyword>
  <keyword>diabetes</keyword>
  <keyword>dietary supplements</keyword>
  <keyword>Senile Dementia, Alzheimer Type</keyword>
  <keyword>Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 subjects did not meet entry criteria and were not baselined</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NIC5-15</title>
          <description>NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects. Subjects received escalating doses of 1500, 3000 and 5000 mg daily over the course of the study.
Subjects with Alzheimer's Disease</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: placebo comparator identical in pill size, appearance and number
Subjects with Alzheimer's Disease</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NIC5-15</title>
          <description>Subjects with Alzheimer's Disease
NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects with Alzheimer's Disease
Placebo: placebo comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="12.5"/>
                    <measurement group_id="B2" value="69.7" spread="13.9"/>
                    <measurement group_id="B3" value="70.05" spread=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Years of Education</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="4.6"/>
                    <measurement group_id="B2" value="18.0" spread="2.0"/>
                    <measurement group_id="B3" value="15.15" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Assessments: Number of Participants With Adverse Events</title>
        <description>vital signs, physical exam, Symptom Checklist, complete blood count, serum chemistries, urinalysis, and electrocardiogram</description>
        <time_frame>Safety Labs, Physical Exams: 6 times over 7 weeks. Adverse Events assessed 21 times over the course of 7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NIC5-15</title>
            <description>Subjects with Alzheimer's Disease
NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with Alzheimer's Disease
Placebo: placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessments: Number of Participants With Adverse Events</title>
          <description>vital signs, physical exam, Symptom Checklist, complete blood count, serum chemistries, urinalysis, and electrocardiogram</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="07"/>
                    <measurement group_id="O2" value="02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Clinical Measures of Cognition at Terminal Visit</title>
        <description>Mini-Mental Status Exam (MMSE) 0(worst)-30(best); ADAS-cog 0 (best cognitive performance across multiple domains) - 70(worst); Activities of Daily Living (ADCS-ADL) 0(least capable of function in daily and instrumental activities)-54(best)</description>
        <time_frame>baseline and six weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NIC5-15</title>
            <description>Subjects with Alzheimer's Disease
NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with Alzheimer's Disease
Placebo: placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Clinical Measures of Cognition at Terminal Visit</title>
          <description>Mini-Mental Status Exam (MMSE) 0(worst)-30(best); ADAS-cog 0 (best cognitive performance across multiple domains) - 70(worst); Activities of Daily Living (ADCS-ADL) 0(least capable of function in daily and instrumental activities)-54(best)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" spread="1.02"/>
                    <measurement group_id="O2" value="-5.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAS-cog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.1"/>
                    <measurement group_id="O2" value="5.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADCS-ADLs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2.8"/>
                    <measurement group_id="O2" value="1.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NIC5-15</title>
          <description>Subjects with Alzheimer's Disease
NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects with Alzheimer's Disease
Placebo: placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemic Lab Value</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoglycemic Lab Value</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Low Hemocrit Lab Value</sub_title>
                <description>Patient had chronic anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Scratchy Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort and Pain at Needle Injection Site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bleeding from Scratch on Arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hillel Grossman</name_or_title>
      <organization>James J Peters VA Medical Center</organization>
      <phone>718-584-9000 ext 5752</phone>
      <email>hillel.grossman2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

